Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, ...

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.80% ...

Equities researchers at Leerink Partners initiated coverage on shares of MannKind (NASDAQ:MNKD – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat reports.

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...

Geron Corp (GERN) stock saw a modest uptick, ending the day at $4.45 which represents a slight increase of $0.06 or 1.37% from the prior close of $4.39. The stock opened at $4.39 and touched a low of ...

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock. The ...

Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, expected in April 2025. Immunic hosted a Multiple Sclerosis (MS ...